Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.

@article{Genugten2009DoesGP,
  title={Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.},
  author={Renate E. van Genugten and Dani{\"e}l H van Raalte and Michaela Diamant},
  journal={Diabetes research and clinical practice},
  year={2009},
  volume={86 Suppl 1},
  pages={S26-34}
}
Type 2 diabetes (T2DM) is a heterogeneous syndrome, characterized by beta-cell failure in the setting of obesity-related insulin resistance. T2DM has a progressive course and is associated with a high cardiovascular disease (CVD) risk, regardless of the treatment used. The incretin hormones glucagon-like peptide (GLP)-1 and glucose-dependent insulinotropic polypeptide (GIP) are secreted in the gut upon meal ingestion and lower blood glucose by glucose-dependent stimulation of insulin secretion… CONTINUE READING
10 Citations
48 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 48 references

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea, Diabetes Care

  • D.M.Kendall, M.C.Riddle, J.Rosenstock, D.L.Zhuang, D.D.Kim, M.S.Fineman
  • 2005
Highly Influential
11 Excerpts

One - Year Treatment With Exenatide Improves Beta - Cell Function , Compared To Insulin Glargine , In Metformin Treated Type 2 Diabetes Patients : A Randomized , Controlled Trial

  • M. Diamant Bunck, A. Corner, B. Eliasson, J. L. Malloy, R. M. Shaginian
  • Diabetes Care
  • 2009

One-Year Exenatide Therapy, Compared With Insulin Glargine, Reduces Postprandial Oxidative Stress in Metformin-Treated Patients With Type 2 Diabetes, Diabetes

  • M.C.Bunck, A.Corner, B.Eliasson, Y.wu, R.M.Shaginian, P.yan
  • 2009
2 Excerpts

Exenatide improves postprandial hyperglycaemia and dyslipidaemia in metformin treated patients with type 2 diabetes

  • A. Corner Bunck, M. Diamant, B. Eliasson, J. L. Malloy, R. M. Shaginian
  • Diabetologi a
  • 2008

Similar Papers

Loading similar papers…